Welcome to our dedicated page for Picard Medical SEC filings (Ticker: PMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Picard Medical, Inc. (PMI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Picard Medical is a Delaware corporation listed on the NYSE American, and its filings describe a business conducted through SynCardia Systems, LLC, a medical technology company that manufactures and sells the SynCardia Total Artificial Heart (STAH) for patients with advanced heart failure.
Through documents such as Form S-1 registration statements and Form 8-K current reports, investors can review detailed information about Picard Medical’s operations, financing arrangements, and risk factors. The S-1 filing explains that SynCardia’s platform includes the SynCardia 50cc and 70cc total artificial hearts, external drivers, ancillary hardware, and associated surgeon and center training. It also notes that the company’s customers are major medical centers operating heart transplant and mechanical circulatory support programs and that SynCardia operates an ISO 13485–certified quality management system.
Form 8-K filings for Picard Medical include disclosures on material definitive agreements, such as senior secured notes and warrant financings, bridge financing arrangements, and related security agreements. Additional 8-Ks furnish press releases and presentation materials related to clinical and technical updates on the next-generation, fully implantable Emperor Total Artificial Heart, as well as corporate events like conference presentations and exchange bell-ringing ceremonies.
On this page, users can follow real-time updates from EDGAR and use AI-powered summaries to understand the key points in lengthy filings. Forms such as the S-1, 8-K, and any future 10-K annual reports, 10-Q quarterly reports, or proxy statements can provide insight into Picard Medical’s capital structure, governance, risk profile, and the progress of its SynCardia and Emperor total artificial heart platforms. Insider transaction reports on Form 4, when available, can also be reviewed to see changes in beneficial ownership by company insiders.
Picard Medical, Inc. filed an 8-K to share a clinical milestone for its SynCardia Total Artificial Heart. UCSF Health successfully supported a male patient in his twenties with advanced biventricular heart failure for 119 days on the device before a heart transplant on March 14, 2026.
This is the second of five UCSF patients successfully bridged to transplant using the SynCardia Total Artificial Heart, underscoring its role for end-stage heart failure patients awaiting donor organs. SynCardia’s system is described as the only commercially available total artificial heart in the United States and Canada, with more than 2,100 implants across 27 countries.
Picard Medical, Inc., parent of SynCardia Systems, highlights a landmark clinical case using the SynCardia Total Artificial Heart. A 29-year-old patient with severe biventricular heart failure lived for more than four years supported entirely by the device, totaling 1,636 days, before receiving a successful donor heart transplant on February 24, 2026.
The SynCardia Total Artificial Heart is indicated as a bridge to transplant for patients with irreversible biventricular heart failure who cannot be managed with left ventricular assist devices alone. It replaces both ventricles and all four native heart valves to restore circulation and hemodynamic stability while patients await a donor organ.
Picard notes that more than 2,100 SynCardia Total Artificial Heart implants have been performed worldwide across 27 countries. The technology is described as the first total artificial heart approved by both the U.S. FDA and Health Canada and the only commercially available artificial heart in the United States and Canada.
Picard Medical, Inc. reported the results of a special meeting of stockholders held virtually by live webcast on March 10, 2026. Stockholders of record as of February 6, 2026, when 73,701,176 common shares were outstanding and entitled to vote, were eligible to participate. Approximately 57.16% of these shares were represented in person via internet webcast or by proxy, indicating a solid turnout for the meeting. Two proposals were voted on, with each receiving about 41.7 million votes in favor, fewer than 0.4 million votes against, and very few abstentions, reflecting strong support among participating shareholders.
Picard Medical, Inc. filed a report describing a media appearance featuring its SynCardia Total Artificial Heart. The company will be highlighted on BTV – Business Television in a segment airing on FOX Business News on March 14, 2026 at 5:00 p.m. Eastern Time.
The segment will showcase the SynCardia Total Artificial Heart, which has been implanted in more than 2,100 patients worldwide and is designed to replace both ventricles and all four heart valves for those awaiting heart transplantation. It will also discuss development of a next-generation, fully implantable artificial heart platform aimed at improving patient mobility and quality of life.
Picard Medical, Inc. announced it will host a webcasted Annual Business Update on March 25, 2026 at 4:30 p.m. Eastern Time. During the event, management will review fiscal year and fourth quarter 2025 financial results, discuss operational progress, commercial activity, and strategic priorities.
The webcast will also feature perspectives from leading clinicians and a patient testimonial regarding the SynCardia Total Artificial Heart. Registration is available via a link in the company’s March 12, 2026 press release and on its website, with the press release furnished as Exhibit 99.1.
Picard Medical, Inc., parent of SynCardia Systems, announced that Vice President of Clinical Affairs Dr. Andre Simon will deliver three presentations at the Technology and Heart Failure Therapeutics 2026 conference in Boston from March 2 to March 4, 2026.
The talks will cover new in vitro and in vivo data for the fully implantable Emperor electromechanical total artificial heart, perspectives on the future of total artificial heart therapy, and updated clinical outcomes with the SynCardia Total Artificial Heart that extend beyond survival to organ recovery, functional improvement, and preservation of transplant eligibility.
Picard Medical, Inc., parent of SynCardia Systems, announced it will participate in the inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics 2026 conference in Boston on March 1, 2026. The session focuses on real-world use of the SynCardia Total Artificial Heart in advanced heart failure.
Senior Clinical Specialists Lauren Wallace and Skyler Peffly will lead small-group, case-based training using the Companion 2 Driver, Freedom Portable Driver, and the SynCardia Total Artificial Heart. SynCardia’s technology has been implanted in more than 2,100 patients across 27 countries and is described as the only commercially available total artificial heart in the United States and Canada.
Picard Medical, Inc. is asking shareholders at a virtual Special Meeting on March 10, 2026 to approve two corporate actions: an amendment to increase authorized common stock to 300,000,000 shares and stockholder approval to permit issuance in excess of 20% of outstanding shares under a purchase agreement with the Selling Stockholders to satisfy NYSE American Rule 713.
As of February 6, 2026, 73,701,176 shares were outstanding. The company disclosed an initial $15,000,000 note issuance under a facility permitting up to an additional $35,000,000, initial warrants to purchase 7,009,346 shares, and conversion-related issuances of 9,990,654 shares. The Board unanimously recommends votes FOR both proposals.
Picard Medical, Inc. is asking stockholders at a special virtual meeting on March 10, 2026 to approve an amendment to its Certificate of Incorporation to increase authorized capital stock from 180,000,000 to 330,000,000 shares, including an increase in authorized common stock from 150,000,000 to 300,000,000 shares. As of February 6, 2026, 73,701,176 shares of common stock were outstanding, with additional shares reserved for an equity incentive plan, warrants and senior secured notes. The board says the increase is intended to provide flexibility to meet existing share issuance obligations and to support future financing and strategic transactions, while noting potential dilution and anti-takeover effects. The board unanimously recommends voting in favor of the proposal.
Picard Medical, Inc. received a large shareholder disclosure from Hudson Bay Capital Management LP and Sander Gerber. They report beneficial ownership of 7,009,346 shares of common stock, all issuable upon exercise of warrants, representing 8.68% of the common stock.
The percentage is based on 73,701,176 shares outstanding as of November 10, 2025, as stated in Picard Medical’s Form 10-Q, and assumes exercise of the warrants held by HT Investments MA LLC. The stake is reported on a passive basis and certified as acquired and held in the ordinary course of business, not to change or influence control of the company.